Plains All American Pipeline (PAA)
(Real Time Quote from BATS)
$18.62 USD
+0.09 (0.49%)
Updated Jul 9, 2024 03:48 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
PAA 18.62 +0.09(0.49%)
Will PAA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PAA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PAA
Zacks Industry Outlook Highlights Enterprise Products Partners, Energy Transfer and Plains All American Pipeline
3 Oil & Gas Pipeline Stocks Benefiting From Industry Prosperity
PAA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Plains All American Pipeline (PAA) a Great Value Stock Right Now?
Are Oils-Energy Stocks Lagging Marathon Oil (MRO) This Year?
Is Enterprise Products Partners (EPD) a Great Value Stock Right Now?
Other News for PAA
Plains All American Pipeline and Plains GP Holdings Announce Quarterly Distributions and Timing of Second-Quarter 2024 Earnings
Plains All American’s 2023 Schedule K-3 Now Available
PharmAust Limited Eyes Growth in Neurodegenerative Market
Pharmaust Limited Issues 5M Unlisted Options
Pharmaust Limited Boosts Investor Relations